NeuroSense jumps on data from combination platform therapy for Alzheimer's

Neurosense Therapeutics

19/01/2023 15:33

** Shares of NeuroSense Therapeutics Ltd  NRSN.O  double to
$2.50
    ** Stock top pct. gainer across U.S. stock exchanges
    ** The Israel-based drug developer reports positive final
results from biomarker study of its combination platform therapy
in Alzheimer's disease (AD) treatment
    ** Final results, which include data from a larger healthy
control group, were in line with preliminary results, showing
the therapy's mechanism of action may be effective to treat the
disease   
    ** Co says mid-stage proof-of-concept trial expected to
commence in H1'23
    ** In 2022, NRSN stock was down 50.4%
 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))